Advertisement

Hormones

pp 1–8 | Cite as

A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture

  • Paschou SAEmail author
  • Theodoros Alexandrides
Review
  • 131 Downloads

Abstract

The aim of this article is to review and present the most important studies published in the field of type 2 diabetes mellitus (T2DM) during 2018. These studies were presented in a lecture given on this topic at the Endorama Meeting in Patras, Greece, in January 2019. In order to identify the most important and relevant articles, a search in the English language was conducted in PubMed for publications up to the end of December 2018, with special attention paid to publications in high impact factor journals. The highlights of the main Diabetes Meetings [ADA (American Diabetes Association) and EASD (European Association of Diabetes)], as well as Medscape, were also reviewed. Last but not least, press releases regarding advances in the diagnosis and treatment of T2DM were considered. We finally selected and discussed important studies concerning diagnosis, pathophysiology, and management of this very common clinical entity (19 studies). The majority of studies were clinical trials dealing with new therapeutic tools for treatment of the disease, with the greatest focus being on GLP-1RA. We also presented in brief the main points of new guidelines published for T2DM by various scientific societies (3 sets of guidelines). During 2018, not only leading diabetes associations published guidelines on the disease, but also societies belonging to other primary scientific fields. This is indicative of the awareness of physicians and scientists that T2DM constitutes today a major health problem and of the need for public health strategies for its treatment and prevention.

Keywords

Type 2 diabetes mellitus 2018 Insulin GLP-1RA SGLT-2i DPP-4i Metformin Guidelines 

Notes

Compliance with ethical standards

Competing interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    Diabetes. World Health Organization (WHO) https://www.who.int/health-topics/diabetes. Last accessed on 09 September 2019.
  2. 2.
    Clinical Trials on Diabetes. https://clinicaltrials.gov/ct2/results?cond=diabetes&term=&cntry=&state=&city=&dist=. Last accessed on 09 September 2019.
  3. 3.
    Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P, Wessman Y, Shaat N, Spégel P, Mulder H, Lindholm E, Melander O, Hansson O, Malmqvist U, Lernmark Å, Lahti K, Forsén T, Tuomi T, Rosengren AH, Groop L (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369CrossRefGoogle Scholar
  4. 4.
    Peddinti G, Bergman M, Tuomi T, Groop L (2019) 1-hour post-OGTT glucose improves the early prediction of type 2 diabetes by clinical and metabolic markers. J Clin Endocrinol Metab 104(4):1131–1140CrossRefGoogle Scholar
  5. 5.
    Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q (2018) Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med 379(7):623–632CrossRefGoogle Scholar
  6. 6.
    Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM, Mateo-Gallego R, Casasnovas JA, Guallar-Castillon P, Cenarro A, Civeira F (2019) Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Diabetes Care 42(2):303–310CrossRefGoogle Scholar
  7. 7.
    Li J, Rice MS, Huang T, Hankinson SE, Clevenger CV, Hu FB, Tworoger SS (2018) Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 61(12):2549–2560CrossRefGoogle Scholar
  8. 8.
    Anagnostis P, Christou K, Artzouchaltzi AM, Gkekas NK, Kosmidou N, Siolos P, Paschou SA, Potoupnis M, Kenanidis E, Tsiridis E, Lambrinoudaki I, Stevenson JC, Goulis DG (2019) Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol 180(1):41–50CrossRefGoogle Scholar
  9. 9.
    Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C (2018) Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 24(12):1919–1929CrossRefGoogle Scholar
  10. 10.
    Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM (2019) Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357CrossRefGoogle Scholar
  11. 11.
    Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M (2019) McGuire DK; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 321(1):69–79CrossRefGoogle Scholar
  12. 12.
    Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6(11):859–869CrossRefGoogle Scholar
  13. 13.
    Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605–617CrossRefGoogle Scholar
  14. 14.
    Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z (2018) Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 6(5):370–381CrossRefGoogle Scholar
  15. 15.
    Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 392(10157):1519–1529CrossRefGoogle Scholar
  16. 16.
    Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A (2018) Viljoen A; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6(4):275–286CrossRefGoogle Scholar
  17. 17.
    Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR (2018) A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care 41(9):1926–1937CrossRefGoogle Scholar
  18. 18.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 392(10160):2180–2193CrossRefGoogle Scholar
  19. 19.
    Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L (2019) Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol 7(3):179–188CrossRefGoogle Scholar
  20. 20.
    ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379(16):1540–1550CrossRefGoogle Scholar
  21. 21.
    ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379(16):1529–1539CrossRefGoogle Scholar
  22. 22.
    Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669–2701CrossRefGoogle Scholar
  23. 23.
    Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS (2018) 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 72(24):3200–3223CrossRefGoogle Scholar
  24. 24.
    Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, Cano A, Chedraui P, Goulis DG, Lopes P, Mishra G, Mueck A, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tuomikoski P, Paschou SA, Anagnostis P, Lambrinoudaki I (2018) Menopause and diabetes: EMAS clinical guide. Maturitas 117:6-10.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2019

Authors and Affiliations

  1. 1.Division of Endocrinology and Diabetes, “Aghia Sophia” Hospital, Medical SchoolNational and Kapodistrian University of AthensAthensGreece
  2. 2.Department of Endocrinology, University Hospital, Medical SchoolUniversity of PatrasPatrasGreece

Personalised recommendations